Akero Therapeutics Inc (AKRO) - Total Liabilities
Based on the latest financial reports, Akero Therapeutics Inc (AKRO) has total liabilities worth $47.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AKRO cash flow metrics to assess how effectively this company generates cash.
Akero Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Akero Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Akero Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Akero Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PTT GLBL CHEM.-NVDR- BA10
F:GCB1
|
Germany | €310.60 Billion |
|
Energy Fuels Inc
NYSE MKT:UUUU
|
USA | $731.35 Million |
|
Patterson-UTI Energy Inc
NASDAQ:PTEN
|
USA | $2.19 Billion |
|
Sotera Health Co
NASDAQ:SHC
|
USA | $2.61 Billion |
|
Grupo Elektra S.A.B. de C.V
MX:ELEKTRA
|
Mexico | MX$441.77 Billion |
|
Axiata Group Bhd
KLSE:6888
|
Malaysia | RM25.70 Billion |
|
Universal Microwave Technology
TWO:3491
|
Taiwan | NT$1.58 Billion |
|
Xian Sunresin New Materials Co Ltd
SHE:300487
|
China | CN¥2.13 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Akero Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Akero Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akero Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akero Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Akero Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $75.77 Million | +68.52% |
| 2023-12-31 | $44.97 Million | +49.84% |
| 2022-12-31 | $30.01 Million | +13.50% |
| 2021-12-31 | $26.44 Million | +80.75% |
| 2020-12-31 | $14.63 Million | +55.74% |
| 2019-12-31 | $9.39 Million | -92.61% |
| 2018-12-31 | $127.07 Million | +2333.36% |
| 2017-12-31 | $5.22 Million | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more